CapsoVision (CV) Corporate presentation summary

Strategic vision and innovation

• Aims to transform GI detection and screening with ingestible capsules for noninvasive, multi-cancer screening using AI image analysis.

• Focuses on delivering endoscopy solutions from esophagus to colon, leveraging panoramic imaging technology.

• Robust intellectual property with 83 issued U.S. patents and a strong commitment to innovation.

Product portfolio and technology

• CapsoCam Plus offers 360° panoramic, wire-free small bowel visualization, FDA cleared and sold globally.

• Superior image quality compared to competitors, with direct mucosal view and less data loss.

• Proprietary AI technology assists physicians and is pending regulatory clearance.

• CapsoCam Colon targets noninvasive colon visualization, with FDA submissions for Gen 1 and Gen 2.

Market opportunity and commercialization

• Small bowel capsule endoscopy market forecasted to reach $335M by 2030; CapsoCam Plus revenue projected at $13.6M in 2025 with 15% YoY growth.

• Colon capsule endoscopy market estimated at $1B, driven by Medicare reimbursement and targeting patients at higher risk or with incomplete colonoscopies.

• Direct sales force in the U.S. and indirect distribution internationally, focusing on hospitals and GPOs.